View Older Stories View More Recent Stories

Jul 29, 2019 08:30AM Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
Jun 4, 2019 07:47AM Allogene Therapeutics (ALLO) Reports FDA Clearance of the IND for ALLO-715
Jun 4, 2019 07:45AM Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
Jun 4, 2019 07:45AM Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
May 29, 2019 08:30AM Allogene Therapeutics Announces June 2019 Investor Conference Schedule
May 29, 2019 08:30AM Allogene Therapeutics Announces June 2019 Investor Conference Schedule
May 7, 2019 07:30AM Allogene Therapeutics Reports First Quarter 2019 Financial Results
May 7, 2019 07:30AM Allogene Therapeutics Reports First Quarter 2019 Financial Results
May 1, 2019 08:30AM Allogene Therapeutics Announces Expansion of Scientific Advisory Board
May 1, 2019 08:30AM Allogene Therapeutics Announces Expansion of Scientific Advisory Board
Apr 30, 2019 08:30AM Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Apr 30, 2019 08:30AM Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Apr 15, 2019 08:08AM Allogene Therapeutics (ALLO) Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 in MM
Apr 15, 2019 08:00AM Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Apr 15, 2019 08:00AM Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Apr 11, 2019 07:00AM AskBio Partners with TPG and Vida Ventures
Apr 3, 2019 04:30PM Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
Apr 3, 2019 04:30PM Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
Apr 1, 2019 01:01PM Allogene Therapeutics (ALLO) Highlgihts Preclinical Data Demonstrating the Potential of AlloCAR T Therapy in Renal Cell Carcinoma at AACR Meeting
Apr 1, 2019 01:00PM Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Apr 1, 2019 01:00PM Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Mar 8, 2019 08:00AM Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Mar 8, 2019 08:00AM Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 27, 2019 08:00AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
Feb 27, 2019 08:00AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
Feb 20, 2019 08:00AM Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
Feb 20, 2019 08:00AM Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
Feb 5, 2019 08:00AM Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Feb 5, 2019 08:00AM Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Jan 28, 2019 08:32AM Allogene Therapeutics (ALLO) Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T Therapy
Jan 28, 2019 08:30AM Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
Jan 28, 2019 08:30AM Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
Dec 19, 2018 08:00AM Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 19, 2018 08:00AM Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 4, 2018 05:50AM Allogene Therapeutics (ALLO), Servier Announce Pooled Data from Phase 1 Trials of Allogeneic UCART19
Dec 3, 2018 07:45PM Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  
Dec 3, 2018 07:45PM Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  
Dec 3, 2018 10:35AM Allogene Therapeutics (ALLO) Presents Data from Preclinical Study of ALLO-715 Demonstrating Allogeneic CAR T Potential in MM at ASH
Dec 3, 2018 10:30AM Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Dec 3, 2018 10:30AM Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Nov 5, 2018 09:00AM Carbon Announces Strategic Updates to Its Board of Directors, Names New Chief Financial Officer
Nov 5, 2018 08:00AM Allogene Therapeutics Announces November 2018 Investor Conference Schedule
Nov 5, 2018 08:00AM Allogene Therapeutics Announces November 2018 Investor Conference Schedule
Nov 1, 2018 09:26AM Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting
View More Recent Stories View Older Stories